Cutaneous response to dinitrochlorobenzene in patients with genito-urinary cancers.
The aim of the present study is to analyse the response in patients with cancer of the urogenital region to a primary antigen 2-4 dinitrochlorobenzene (DNCB). A total of 69 patients with neoplastic disease were studied (13 cases with kidney cancer, 34 cases with bladder cancer, 13 cases with prostatic cancer, 5 cases with testicular cancer, one case with penis cancer, and 3 cases with cancer of the cervix, comparatively with 13 patients with non-malignant urological diseases. Whereas in the control group, 78% of the patients gave a positive skin reaction to DNCB, 15% of the patients with kidney cancer, 56% of the patients with bladder cancer, 69% of the patients with prostatic cancer and 60% of the patients with testicular cancer gave a positive reaction.  If we consider the stages of the disease, the reaction was positive, in 91% of bladder cancer at stage I and in 47% at stages II and III in 100% of prostatic cancer at stage I and in 62% at stages II and III, in 60% of testicular cancer at stage IV (but 100% of seminomas and 0% of dysembryomas have a positive reaction). It would therefore seem that a correlation exists between the degree of the extension of the disease and the skin reaction to DNCB.
D004137:Dinitrochlorobenzene; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007680:Kidney Neoplasms / Q000276:immunology; D008297:Male; D009578:Nitrobenzenes; D010412:Penile Neoplasms / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology; D012867:Skin / Q000276:immunology*; D013736:Testicular Neoplasms / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology; D014565:Urogenital Neoplasms / Q000276:immunology*; D014594:Uterine Neoplasms / Q000276:immunology
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes